Guerbet LLC

Since 1901 Guerbet Group has had a long-standing tradition as a pioneer in the research and development of medical imaging contrast media. Headquartered in Paris, France, Guerbet is a publicly traded company holding more than 20% of the European market share and 7% of the worldwide contrast media market.
The Guerbet product portfolio is marketed in 130 countries worldwide and contains contrast agents for X-ray and MRI modalities: Oxilan®, Hexabrix®(1), Dotarem®(2), Lumirem®(2), Endorem®(2) and others. Guerbet dedicates the best talent and resources to new drug development, currently having multiple agents in Phase III clinical trials.

Guerbet LLC, the U.S. subsidiary was established in February of 2002 by purchasing the assets of Oxilan from Cook®, one of the leaders in the medical device industry. Currently Guerbet LLC is responsible for the marketing, sales and distribution of Oxilan® (Ioxilan Injection), a non-ionic contrast media for diagnostic and interventional imaging. In addition, steps are underway to seek approval for new products in the U.S. market, beginning with an extracellular MR agent and an MR blood pool agent in the future.

Contact Details: 1185 West 2nd Street Bloomington Indiana 47403-2160 United States of America Tel: 812-333-0059 Fax: 812-333-0084 Email: info-us@guerbet-group.com WWW: www.guerbet.ch/

Loading...

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 175 times since April 2007, the link to the organisation's website has been followed 23 times

Search for more companies in Bloomington

Search for more companies in Indiana

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Guerbet LLC